Shopping Cart
- Remove All
- Your shopping cart is currently empty
ACY-1083 is a selective, brain-penetrating HDAC6 inhibitor (IC50: 3 nM) that effectively reverses chemotherapy-induced peripheral neuropathy.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $155 | In Stock | |
5 mg | $328 | In Stock | |
10 mg | $559 | In Stock | |
25 mg | $883 | In Stock | |
50 mg | $1,230 | In Stock | |
100 mg | $1,660 | In Stock | |
500 mg | $3,330 | In Stock | |
1 mL x 10 mM (in DMSO) | $363 | In Stock |
Description | ACY-1083 is a selective, brain-penetrating HDAC6 inhibitor (IC50: 3 nM) that effectively reverses chemotherapy-induced peripheral neuropathy. |
Targets&IC50 | HDAC6:3 nM |
In vitro | ACY-1083 (30 and 300 nM) dose-dependently improves cell viability[2]. |
In vivo | In C57BL/6J mice, ACY-1083 (10 mg/kg; i.p.) effectively relieves Cisplatin-induced mechanical allodynia. In adult male SD rats, ACY-1083 (3 mg/kg; orally) reverses Paclitaxel-induced mechanical allodynia. ACY-1083(5 mg/kg; i.p.) shows a Cmax of 936 ng/mL, a half-life (T1/2) of 3.5h, and a biologically active plasma exposure of 8 hours[1]. |
Molecular Weight | 348.35 |
Formula | C17H18F2N4O2 |
Cas No. | 1708113-43-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 180 mg/mL (516.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.